The Center for Biomedical Innovation at MIT just released its first newsletter, with two key announcements. The healthcare think tank now counts a number of leading pharma companies, including Novartis, among its members. First announcement: Former FDA Commissioner Scott McClelland will be joining its Strategy and Policy Council. Mark McCllellan, M.D., Ph.D., former Commissioner of the FDA and Administrator for the Centers for Medicare and Medicaid Services, has joined the CBI Strategy & Policy Council. Prior to joining the FDA, Dr. McClellan was Associate Professor of Economics at Stanford University, Associate Professor of Medicine at Stanford Medical School, a practicing internist, and Director of the Program on Health Outcomes Research at Stanford University.The Strategy & Policy Council serves as a major advisory committee, helping to guide CBI research activities and the development of initiatives and projects. The Center's Director, Frank Douglas, a pre-eminent researcher and Harvard professor, has been elected a Black History Maker for 2007.